In patients with heart failure, both with and without diabetes, dapagliflozin was shown to provide identical efficacy and possibly beneficial effects on the heart, said John McMurray, MD, FRCP, FESC, professor of medical cardiology in the Institute of Cardiovascular and Medical Sciences at the University of Glasgow.
In patients with heart failure, both with and without diabetes, dapagliflozin was shown to provide identical efficacy and possibly beneficial effects on the heart, said John McMurray, MD, FRCP, FESC, professor of medical cardiology in the Institute of Cardiovascular and Medical Sciences at the University of Glasgow.
Transcript
Why would the heart failure benefits of dapagliflozin be nearly identical for patients with and without diabetes?
The benefits of dapagliflozin were identical in patients with and without diabetes, and even more so, among the patients without diabetes, the benefits of dapagliflozin were consistent right across the spectrum of glycated hemoglobin. So, even patients with a completely normal hemoglobin A1C got as much benefit as other patients. Clearly, that questions the idea that in heart failure, this is just about lowering glucose. In fact, the patients without diabetes, randomized to dapagliflozin, had no reduction in hemoglobin A1C either—again, questioning the benefits in heart failure just being about reducing glucose. So, the alternative possibilities are that these agents do have, at least in the short term, a diuretic effect–that might be beneficial, but it's unlikely to be the whole explanation.
These drugs do protect the kidneys, slow the progressive deterioration of renal function that we see in patients with heart failure, and we've reported that with dapagliflozin, both in patients with and without diabetes. Then I think the third idea, at least, is that these drugs might have beneficial effects on the heart. Now, these are largely still in human beings’ hypotheses, but probably the 2 major ones are, firstly, that these drugs might improve myocardial energetics, make the heart more metabolically efficient, and then that way work better. One reason why that might be is because they increase the production of ketones. You can think of ketones, the very simplistic way, as a super fuel for the heart that are more metabolically efficient. Then the other explanation, but again, very hypothetical and experimental, is that SGLT2 inhibitors might interact with what's called the sodium hydrogen exchanger on heart muscle cells, cardiomyocytes. By reducing intracellular sodium, might, for example, reduce the risk of sudden death; but we don't have any firm human evidence for that—it's a speculative mechanism.
Survey Results Reveal Potential Factors Slowing the Decline in Cardiovascular Mortality Rate
April 23rd 2024Research indicated that worsened glycemic, blood pressure, and obesity control, as well as increased alcohol consumption, leveled lipid control, and persistent socioeconomic disparities may have contributed to the decelerated cardiovascular mortality decline in recent years.
Read More
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
Beyond Insulin: The Impact of Next-Generation Diabetes Technology
April 17th 2024Experts explain how new diabetes technologies like continuous glucose monitors are transforming care beyond intensive insulin therapy, offering personalized insights and improving outcomes for patients of all treatment levels.
Read More
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Dr Michael Farwell on FDG PET/CT Imaging to Predict Immunotherapy Response in Advanced Melanoma
April 15th 2024Michael Farwell, MD, associate professor of radiology at the Hospital of the University of Pennsylvania, provides insights into a study on the benefits of using 18F-fluorodeoxyglucose (FDG) PET/CT imaging to detect metabolic tumor changes in skin cancer.
Read More
Real-World Data Show Leqvio's Effectiveness in Reducing LDL-C in Patients With ASCVD
April 11th 2024Results from the V-INITIATE trial showed a substantial 60% reduction in low-density lipoprotein cholesterol (LDL-C) from baseline to day 330 in the inclisiran first group compared with a mere 7% reduction in the usual care group.
Read More